Curated News
By: NewsRamp Editorial Staff
September 11, 2024
Aclarion, Inc. (NASDAQ: ACON) Leading Innovation in Back Pain Management
Discuss on Reddit
Discuss on LinkedIn
Discuss on SubstackTLDR
- ACON's Nociscan platform offers a competitive advantage in noninvasive diagnosis and treatment planning for chronic low back pain.
- Nociscan uses MRS, signal processing, and AI algorithms to noninvasively differentiate painful and nonpainful discs in the lumbar spine.
- Nociscan's advanced diagnostic technology enhances treatment planning, leading to improved patient care and better outcomes for chronic low back pain.
- Aclarion's Nociscan platform represents a groundbreaking advancement in noninvasive diagnosis and management of chronic low back pain.
Impact - Why it Matters
This news matters as ACON's Nociscan platform has the potential to revolutionize the diagnosis and management of chronic low back pain, impacting millions worldwide. The company's advancements and partnerships could lead to improved patient care, more precise diagnostics, and potentially cost-effective treatment options, signaling a significant shift in the healthcare technology sector.
Summary
Aclarion, Inc. (NASDAQ: ACON) is making strides in addressing chronic low back pain with its Nociscan platform, a groundbreaking diagnostic tool utilizing Magnetic Resonance spectroscopy and AI algorithms. The company has achieved a significant milestone with the completion of the first Nociscan exams in the LIFEHAB trial, a pivotal study comparing surgical and non-surgical treatment for cLBP. ACON has also expanded its presence in the US market, securing a commercial agreement with Sheridan Community Hospital in Michigan and entering the personal injury and workers’ compensation markets in New Jersey.
Source Statement
This curated news summary relied on this press release disributed by News Direct. Read the source press release here, Aclarion, Inc. (NASDAQ: ACON) Leading Innovation in Back Pain Management
